David A. Mankoff

Has grant

Matthew J Wilson Professor and Research Vice-Chair of Radiology

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

ACC-PREP: Proposal for ACS DICR Post-Bac Program

Open Date: 2024-01-01

Close Date: 2026-12-31

Articles (29)

Year:

2026

The ternary complex of progesterone receptor membrane component 1 (PGRMC1)–sigma-2 receptor/transmembrane protein 97 (σ2R/TMEM97)–low-density lipoprotein receptor (LDLR) has recently been discovered and plays a role in cholesterol transport. This study investigated whether individual components of that complex are prognostic breast cancer biomarkers and have defined expression in established molecular subtypes. A total of 4,463 invasive breast cancers were analyzed as a function of molecular and phenotypic markers, estimates of cellular proliferation, and recurrence-free survival. A gene expression signature–based assay was utilized to estimate cellular proliferation. Cox proportional hazards regression estimated relapse-free survival and multivariate Cox analysis adjusted for the association of proliferation with early relapse. PGRMC1–σ2R/TMEM97–LDLR expression was stratified by immunohistochemical (IHC) and molecular subtype, tumor grade, and size. TMEM97 exhibited the strongest correlation with proliferation, highest in estrogen receptor (ER)–positive disease (r = 0.59, P = 8.1−114). TMEM97 and PGRMC1 were associated with a risk of early recurrence, dependent upon their association with proliferation. The risk of early recurrence was highest with TMEM97 and only seen in ER+/HER2− disease [HR = 1.5; 95% confidence interval (CI) = 1.35–1.67; P = 5.4−14] and ER+ malignancies (HR = 1.49; 95% CI = 1.31–1.68; P = 3.1−10). There was no increased risk of recurrence with TMEM97 expression in ER−/HER2− (HR = 1.05; 95% CI = 0.88–1.25; P = 0.63) or ER− disease (HR = 1.02; 95% CI = 0.89–1.17; P = 0.75). Components of a ternary complex associated with rapid internalization of low-density lipoprotein are biomarkers associated with cellular proliferation and early recurrence, which should help guide studies exploring them in the context of additional markers of aggressive disease. Elucidating the role of PGRMC1, TMEM97, and LDLR in breast cancer will facilitate a mechanistic understanding of how proliferation interplays with cholesterol metabolism in malignant transformation or propagation. Significance: This first large-scale analysis of the putative ternary complex responsible for rapid low-density lipoprotein internalization in breast cancer reveals a link between component expression and recurrence, with prognostic implications for identifying patients needing supplemental posttreatment surveillance and/or additional therapeutic approaches.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Trimethoprim (TMP) is a reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR) used for the treatment or prophylaxis of bacterial infections. [ 11 C]trimethoprim ([ 11 C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP. TMP binds with 30,000-fold greater affinity to bacterial DHFR over the homologous mammalian enzyme in vitro , suggesting [ 11 C]TMP may selectively accumulate in tissues with cells expressing bacterial DHFR. This study characterizes the biodistribution and dosimetry of [ 11 C]TMP, informing its use in imaging bacterial infections and tracking mammalian cells expressing eDHFR as a reporter gene. Methods Four males with suspected infection, aged 59 ± 10 years old (mean ± SD) received 3 serial PET/CT scans after injection of 346 ± 305 MBq (range 129–797 MBq) of [ 11 C]TMP. Organ activities were measured in MIM v6.7, including brain, kidneys, spleen, liver, heart, lungs, bladder, intestines, gallbladder, pancreas, thyroid, and red marrow. Dosimetry calculations were performed in Olinda | EXM v1.1. Additionally, a dynamic whole-body PET/CT scan was performed on a separate participant. The associated trial was registered as NCT03424525. Results [ 11 C]TMP injections were well tolerated with no adverse events. The average injected activity of 346 MBq of [ 11 C]TMP yielded an estimated average dose of 4.9 mSv in the highest uptake organ (liver), 4.1 mSv in the spleen, and an effective dose of 1.6 mSv. Suspected sites of infection displayed uptake above background. Conclusion [ 11 C]TMP PET was safe and demonstrated low background uptake in most tissues. The data suggests feasibility for evaluation of varied bacterial infections, including musculoskeletal infections. Absorbed doses allow multiple [ 11 C]TMP PET scans each year within Radioactive Drug Research Committee (RDRC) limits, potentially enabling monitoring of infections and treatment response.

Year:

2025

Background 18 F-Fluorodeoxyglucose (FDG) and 18 F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) positive metastatic breast cancer (MBC), but little is known about its utility in patients with breast tumors that overexpress human epidermal growth factor 2 (HER2). We hypothesize that comparing patterns of FDG and FES uptake in patients with HER2-positive versus HER2-negative MBC can guide further biologic and clinical studies into the HR/HER2-positive phenotype. Methods We conducted a retrospective study examining uptake in matched lesions for FES and FDG-PET scans, assessing these parameters in 213 patients with ER-positive/HER2-positive ( n = 33) versus ER-positive/HER2-negative MBC ( n = 180). We employed log-rank and t-tests to assess the association of HER2 status with outcome variables and the hypotheses that patients expressing HER2-positive disease lived longer than patient with HER2-negative disease. Results No difference in FES or FDG avidity was observed between patients with HER2-negative or HER2-positive tumor status. Limited data also suggests that patients with HER2-positive disease had better overall survival ( p = 0.024), than those with HER2-negative disease, but not time-to-progression between the same patient cohorts. Conclusion This retrospective analysis suggests that there is a possible role for future trials using FES-PET in helping to select patients with ER+/HER2-positive primary tumors who retain ER expression at all sites of disease and may benefit from endocrine therapy.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Collaborators (23)

Fenghai Duan

Professor

Brown University

UNITED STATES
View details

Mark A. Sellmyer

University of Pennsylvania

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Christopher Hensley

Assistant Professor in Molecular Imaging and Therapeutics

University of Alabama, Tuscaloosa

UNITED STATES
View details

Lainie Martin

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Jennifer Holter Chakrabarty

Associate Professor

University of Oklahoma College of Medicine

UNITED STATES
View details

Robert Mach

Britton Chance Professor

University of Pennsylvania

UNITED STATES
View details

Fiona Simpkins

-

UNITED STATES
View details

Lilie L. Lin

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ramsey Badawi

Professor

university of california davis medical center

UNITED STATES
View details

Jennifer Specht

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Janos Tanyi

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Philipose Mulugeta

Associate Professor of Radiology

University of Pennsylvania

UNITED STATES
View details

Daniel Arber

Professor and Chair

University of Chicago

UNITED STATES
View details

Stephen Strickland

Assistant Professor of Medicine

Vanderbilt University Medical Center

UNITED STATES
View details

Drew Torigian

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Andrew Kossenkov

Assistant Professor

The Wistar Institute

UNITED STATES
View details

JEREMIE CALAIS

Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Lewis Chodosh

Professor and Chairman

University of Pennsylvania

UNITED STATES
View details

Robert Jeraj

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Elizabeth McDonald

University of Pennsylvania

UNITED STATES
View details

Sarah Gitto

Assistant Research Professor

University of Pennsylvania

UNITED STATES
View details